Malignant Pleural Effusions, Pleural Effusion, Tuberculous Pleural Effusion
Conditions
Brief summary
The goal of this observational study is to evaluate the role of pleural fluid Quantitative C-Reactive Protein (Q-CRP) levels in distinguishing between tuberculous and malignant pleural effusion in adult patients with lymphocytic exudative pleural effusion. The main questions it aims to answer are: Is pleural fluid Q-CRP significantly higher in tuberculous pleural effusion compared to malignant pleural effusion? What is the optimal cutoff value of pleural fluid Q-CRP to differentiate between these conditions? Participants will: Undergo diagnostic procedures such as pleural fluid analysis, including ADA and cytology. Provide pleural fluid samples for Q-CRP measurement. Have additional diagnostic imaging or biopsies if clinically indicated. Researchers will compare Q-CRP levels between the tuberculous pleural effusion group and the malignant pleural effusion group to determine its diagnostic accuracy, including sensitivity, specificity, and predictive value.
Interventions
DIAGNOSTIC_TESTPleural Fluid Quantitative C-Reactive Protein (Q-CRP) Measurement
The intervention involves the measurement of Quantitative C-Reactive Protein (Q-CRP) levels in pleural fluid obtained from patients presenting with lymphocytic exudative pleural effusion. The Q-CRP test is performed using standardized laboratory methods to quantitatively analyze CRP levels, which are then compared between patients with confirmed tuberculous pleural effusion and those with malignant pleural effusion. This diagnostic approach aims to evaluate the efficacy of pleural fluid Q-CRP as a biomarker to differentiate between these two conditions. No therapeutic or invasive interventions are introduced as part of this study beyond routine diagnostic procedures.
Sponsors
Maharajgunj Medical Campus
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults aged 18 years and older. * Patients presenting with lymphocytic exudative pleural effusion confirmed by Light's criteria. * Lymphocyte predominance in pleural fluid (≥ 50% of differential count).
Exclusion criteria
* Patients who refuse to provide consent for study participation. * Patients requiring biopsy under general anesthesia but found unfit for the procedure. * Non-tuberculous and non-malignant lymphocytic exudative pleural effusions identified during diagnostic evaluation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Pleural Fluid Quantitative C-Reactive Protein (Q-CRP) Levels Between Tuberculous and Malignant Pleural Effusion | Within 1 year (from November 2022 to October 2023) | The primary outcome is the difference in pleural fluid Quantitative C-Reactive Protein (Q-CRP) levels between patients diagnosed with tuberculous pleural effusion and those with malignant pleural effusion. The study evaluates the diagnostic utility of Q-CRP levels as a biomarker by comparing mean values, sensitivity, specificity, and Area Under the Receiver Operating Characteristic (ROC) curve for differentiation between the two conditions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity and Specificity of Pleural Fluid Q-CRP Cut-off Values for Differentiating Tuberculous and Malignant Pleural Effusion | Within 1 year (from November 2022 to October 2023) | The secondary outcome evaluates the diagnostic performance of pleural fluid Q-CRP cut-off levels derived from the ROC curve analysis. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) are calculated to assess the utility of Q-CRP in accurately differentiating tuberculous pleural effusion from malignant pleural effusion. |
Countries
Nepal
Outcome results
None listed